Tumor Evolution: Progression, Metastasis and Therapeutic Response

A topical collection in Cancers (ISSN 2072-6694). This collection belongs to the section "Molecular Cancer Biology".

Viewed by 9215

Editor


E-Mail
Collection Editor
Biomedical Research Foundation of the Academy of Athens (BRFAA), 11741 Athens, Greece
Interests: genome integrity; epigenetic regulation; gene expression; translation; viruses; molecular virology; viruses’ evolution
Special Issues, Collections and Topics in MDPI journals

Topical Collection Information

Dear Colleagues,

Recent advances in cancer genomics have revealed that solid tumors often consist of multiple genetically and spatially distinct subpopulations. In addition, cancer cells within different subpopulations can evolve, acquiring genetic and epigenetic alterations over time that affect their interactions with the tissue microenvironment and the immune system.

During tumor progression, these evolutionary dynamics have the potential to generate subclones that are resistant to drug therapy or have metastatic potential. Understanding the molecular mechanisms driving cancer heterogeneity, evolution, chemoresistance, invasion, migration and distant colonization is helping us to identify promising biomarkers for therapeutic targeting.

For this Topical Collection of Cancers, we invite authors to submit contributions that provide novel findings in the field of cancer progression and evolution. In particular, we solicit papers providing insights in areas including but not limited to tumor heterogeneity, mutation acquisition, DNA repair, epigenetic deregulation, transcriptional plasticity, chemoresistance and therapeutic response, immune escape, tumor microenvironment, recurrence and metastasis with respect to tumor evolution. Reviews that highlight new findings in the above areas are also welcome.

Dr. Theodoros Rampias
Collection Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the collection website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • tumor heterogeneity
  • clonal evolution
  • mutations
  • metastasis
  • plasticity
  • epigenetics
  • DNA repair
  • chemoresistance
  • genomic instability
  • tumor microenvironment
  • adaptive immune resistance

Related Special Issue

Published Papers (3 papers)

2023

Jump to: 2022

4 pages, 200 KiB  
Editorial
Gene Expression and DNA Methylation as Prognostic Markers in Metastatic Castration-Resistant Prostate Cancer: Analysis of Circulating Tumor Cells and Paired Plasma-Derived Exosomes
by Mohamed Ali Hussein and Gnanasekar Munirathinam
Cancers 2023, 15(22), 5325; https://doi.org/10.3390/cancers15225325 - 8 Nov 2023
Viewed by 1246
Abstract
Prostate cancer (PCa) is the most prevalent cancer among men and is the second leading cause of cancer-related death in the United States [...] Full article

2022

Jump to: 2023

18 pages, 4761 KiB  
Article
FOXC2 Promotes Vasculogenic Mimicry in Ovarian Cancer
by Maria Sol Recouvreux, Jiangyong Miao, Maricel C. Gozo, Jingni Wu, Ann E. Walts, Beth Y. Karlan and Sandra Orsulic
Cancers 2022, 14(19), 4851; https://doi.org/10.3390/cancers14194851 - 4 Oct 2022
Cited by 10 | Viewed by 2383
Abstract
FOXC2 is a forkhead family transcription factor that plays a critical role in specifying mesenchymal cell fate during embryogenesis. FOXC2 expression is associated with increased metastasis and poor survival in various solid malignancies. Using in vitro and in vivo assays in mouse ovarian [...] Read more.
FOXC2 is a forkhead family transcription factor that plays a critical role in specifying mesenchymal cell fate during embryogenesis. FOXC2 expression is associated with increased metastasis and poor survival in various solid malignancies. Using in vitro and in vivo assays in mouse ovarian cancer cell lines, we confirmed the previously reported mechanisms by which FOXC2 could promote cancer growth, metastasis, and drug resistance, including epithelial-mesenchymal transition, stem cell-like differentiation, and resistance to anoikis. In addition, we showed that FOXC2 expression is associated with vasculogenic mimicry in mouse and human ovarian cancers. FOXC2 overexpression increased the ability of human ovarian cancer cells to form vascular-like structures in vitro, while inhibition of FOXC2 had the opposite effect. Thus, we present a novel mechanism by which FOXC2 might contribute to cancer aggressiveness and poor patient survival. Full article
Show Figures

Figure 1

20 pages, 6435 KiB  
Review
Non-Melanoma Skin Cancer: A Genetic Update and Future Perspectives
by Marianela Zambrano-Román, Jorge R. Padilla-Gutiérrez, Yeminia Valle, José F. Muñoz-Valle and Emmanuel Valdés-Alvarado
Cancers 2022, 14(10), 2371; https://doi.org/10.3390/cancers14102371 - 11 May 2022
Cited by 25 | Viewed by 4940
Abstract
Skin cancer is one of the main types of cancer worldwide, and non-melanoma skin cancer (NMSC) is the most frequent within this group. Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are the most common types. Multifactorial features are well-known for cancer [...] Read more.
Skin cancer is one of the main types of cancer worldwide, and non-melanoma skin cancer (NMSC) is the most frequent within this group. Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are the most common types. Multifactorial features are well-known for cancer development, and new hallmarks are gaining relevance. Genetics and epigenetic regulation play an essential role in cancer susceptibility and progression, as well as the variety of cells and molecules that interact in the tumor microenvironment. In this review, we provide an update on the genetic features of NMSC, candidate genes, and new therapies, considering diverse perspectives of skin carcinogenesis. The global health situation and the pandemic have been challenging for health care systems, especially in the diagnosis and treatment of patients with cancer. We provide innovative approaches to overcome the difficulties in the current clinical dynamics. Full article
Show Figures

Figure 1

Back to TopTop